Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 513-519

  Ikeda, Ryuji ^a   Vermeulen, Lee C ^b,c   Lau, Elim ^d   Jiang, Zhisheng ^d   Sachidanandam, Kamakshi ^d   Yamada, Katsushi ^a   Kolesar, Jill M ^d  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

A549 cells; Gemcitabine; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CEPHARANTHINE; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME P450 3A5; DOCETAXEL; GEMCITABINE; HYDROLASE; IRINOTECAN; MICROSOMAL EPOXIDE HYROLASE 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 7; PACLITAXEL; PROTEIN P21; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL ISOLATION; CELL STRUCTURE; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78651237278     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.866     Document Type: Article

References (36)

1. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L and Laurie SA: Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27: 404-410, 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D and Giaccone G: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251-6266, 2009.
4. Heinemann V, Hertel LW, Grindey GB and Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031, 1988.
5. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539, 1992.
6. Furusawa S and Wu J: The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci 80: 1073-1079, 2007.
7. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD and Chen ZS: Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 77: 993-1001, 2009.
8. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ, Palacios J and Moreno-Bueno G: Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 102: 157-172, 2007.
9. Flynn V Jr, Ramanitharan A, Moparty K, Davis R, Sikka S, Agrawal KC and Abdel-Mageed AB: Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 23: 317-323, 2003.
10. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O and Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65: 6934-6942, 2005.
11. Kang HJ, Lee SH, Price JE and Kim LS: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J 15: 223-229, 2009.
12. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS and Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 69: 178-184, 2009.
13. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, Maeda H, Sato S and Ueda R: MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in nonsmall cell lung cancer. Mol Cancer Ther 7: 1150-1155, 2008.
14. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG and Kruh GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64: 4927-4930, 2004.
15. Ikeda R, Che XF, Yamaguchi T, Ushiyama M, Zheng CL, Okumura H, Takeda Y, Shibayama Y, Nakamura K, Jeung HC, Furukawa T, Sumizawa T, Haraguchi M, Akiyama S and Yamada K: Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci 96: 372-376, 2005.
16. Mukai M, Che XF, Furukawa T, Sumizawa T, Aoki S, Ren XQ, Haraguchi M, Sugimoto Y, Kobayashi M, Takamatsu H and Akiyama S: Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci 94: 557-563, 2003.
17. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88: 1963-1970, 2003.
18. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool M, van Soest S, Baas F, ten Brink JB and de Jong PT: Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25: 228-231, 2000.
19. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti I, Pope F M, Richards A, Terry S, Bercovitch L, de Paepe A and Boyd CD: Mutations in a gene encoding an ABC transporter cause Pseudoxanthoma elasticum. Nat Genet 25: 223-227, 2000.
20. Ringpfeil F, Lebwohl MG, Christiano AM and Uitto J: Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 97: 6001-6006, 2000.
21. Struk B, Cai L, Zach S, Ji W, Chung J, Lumsden A, Stumm M, Huber M, Schaen L, Kim C A, Goldsmith LA, Viljoen D, Figuera LE, Fuchs W, Munier F, Ramesar R, Hohl D, Richards R, Neldner KH and Lindpaintner K: Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause Pseudoxanthoma elasticum. J Mol Med 78: 282-286, 2000.
22. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H and Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62: 6172-6177, 2002. (Pubitemid 35244468)
23. Wang T, Chen FY, Gu CH, Zhong H, Teng Y and Ouyang RR: Transfection of HL-60 cells with CYP3A5 gene induces drug-resistant phenotype. Zhonghua Zhong Liu Za Zhi 27: 461-464, 2005.
24. Xie HG, Wood AJ, Kim RB, Stein CM and Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5: 243-272, 2004.
25. Wacher VJ, Wu CY and Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134, 1995.
26. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
27. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
28. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
29. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995.
30. Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
31. Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877-4882, 1997.
32. Suzuki A, Tsutomi Y, Akahane K, Araki T and Miura M: Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17: 931-939, 1998.
33. Steinman RA and Johnson DE: p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med 6: 736-749, 2000.
34. Xu SQ and El-Deiry WS: p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269: 179-190, 2000.
35. Oesch F: Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3: 305-340, 1973.
36. Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, Frankl H, Lee E, Zhu QS, Haile R and Levy D: A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 61: 2381-2385, 2001.